tiprankstipranks
Advertisement
Advertisement

PROK Stock Latest News

ProKidney appoints Kenneth Locke as chief technical officer
The FlyProKidney appoints Kenneth Locke as chief technical officer
1M ago
CARM
PROK
ProKidney shareholders reaffirm board and auditor at 2026 meeting
PremiumCompany Announcements
ProKidney shareholders reaffirm board and auditor at 2026 meeting
1M ago
8K
PROK
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
PremiumRatings
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
2M ago
PROK
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
PremiumCompany Announcements
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
2M ago
8K
PROK
ProKidney reports Q1 EPS (14c), consensus (14c)
PremiumThe Fly
ProKidney reports Q1 EPS (14c), consensus (14c)
2M ago
PROK
ProKidney sees cash runway into mid-2027
PremiumThe FlyProKidney sees cash runway into mid-2027
2M ago
PROK
PROK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
PROK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
PROK
ProKidney appoints Greg Madison as chief commercial officer
Premium
The Fly
ProKidney appoints Greg Madison as chief commercial officer
4M ago
PROK
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
PremiumCompany Announcements
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
4M ago
PROK
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
PremiumRatings
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
4M ago
PROK
ProKidney reports Q4 EPS (52c), consensus (15c)
PremiumThe Fly
ProKidney reports Q4 EPS (52c), consensus (15c)
4M ago
PROK
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
PremiumRatings
Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
5M ago
PROK
ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
PremiumRatingsProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
5M ago
PROK
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
Premium
Company Announcements
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
5M ago
8K
PROK
Advancing Rilparencel in Diabetic CKD: De-Risked PROACT 1 Trial Design and Strong Enrollment Support Buy Rating on ProKidney
Premium
Ratings
Advancing Rilparencel in Diabetic CKD: De-Risked PROACT 1 Trial Design and Strong Enrollment Support Buy Rating on ProKidney
6M ago
PROK
ProKidney Advances Rilparencel Program and Manufacturing Expansion
PremiumCompany Announcements
ProKidney Advances Rilparencel Program and Manufacturing Expansion
6M ago
8K
PROK
ProKidney initiated with a Buy at H.C. Wainwright
PremiumThe Fly
ProKidney initiated with a Buy at H.C. Wainwright
7M ago
PROK
PROK Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
PROK Upcoming Earnings Report: What to Expect?
8M ago
PROK
ProKidney reports Q3 EPS (12c), consensus (14c)
PremiumThe Fly
ProKidney reports Q3 EPS (12c), consensus (14c)
8M ago
PROK
ProKidney presents results from Phase 2 REGEN-007 trial of rilparencel
PremiumThe FlyProKidney presents results from Phase 2 REGEN-007 trial of rilparencel
8M ago
PROK
Prokidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment
Premium
Company Announcements
Prokidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment
9M ago
PROK
Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD
Premium
Company Announcements
Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD
9M ago
PROK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >